Form 4: Boston Scientific EVP Jeffrey Mirviss Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Executive Vice President of Boston Scientific, Jeffrey B. Mirviss, sold shares of common stock under a pre-established Rule 10b5-1 trading plan.
Summary
- On March 18, 2024, Jeffrey B. Mirviss, EVP & President, Periph Intervent at Boston Scientific Corp (BSX), sold common stock.
- The transaction involved the sale of 14,506 shares at a price of $66.4504 per share.
- The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023.
- Following the transaction, Mirviss directly owns 58,098 shares of Boston Scientific common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to insider trading. It doesn't inherently convey positive or negative sentiment, as it simply reports a transaction.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 05/25/2023 | Date of adoption of the Rule 10b5-1 trading plan |
| 03/18/2024 | Date of the transaction (stock sale) |
| 03/19/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.